PMS-LATANOPROST-TIMOLOL SOLUTION

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

TIMOLOL (TIMOLOL MALEATE); LATANOPROST

Disponível em:

PHARMASCIENCE INC

Código ATC:

S01ED51

DCI (Denominação Comum Internacional):

TIMOLOL, COMBINATIONS

Dosagem:

5MG; 50MCG

Forma farmacêutica:

SOLUTION

Composição:

TIMOLOL (TIMOLOL MALEATE) 5MG; LATANOPROST 50MCG

Via de administração:

OPHTHALMIC

Unidades em pacote:

5ML

Tipo de prescrição:

Prescription

Área terapêutica:

BETA-ADRENERGIC AGENTS

Resumo do produto:

Active ingredient group (AIG) number: 0248501002; AHFS:

Status de autorização:

APPROVED

Data de autorização:

2013-04-10

Características técnicas

PRODUCT MONOGRAPH
PR
PMS-LATANOPROST-TIMOLOL
Fixed combination of latanoprost 50 mcg/mL and timolol 5 mg/mL as
timolol
maleate
STERILE OPHTHALMIC SOLUTION
ELEVATED INTRAOCULAR PRESSURE THERAPY
PROSTAGLANDIN F
2Α
ANALOGUE AND BETA-ADRENERGIC RECEPTOR BLOCKER
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Avenue, Suite #100, March 28, 2017
Montréal, Québec
H4P 2T4
www.pharmascience.com
CONTROL NO: 194552
_ _
_ _
_pms-LATANOPROST-TIMOLOL Product Monograph Page 2 of 30 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTION
......................................................................................................
8
DRUG INTERACTIONS
..................................................................................................
12
DOSAGE AND ADMINISTRATION
..............................................................................
13
OVERDOSAGE
................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 14
STORAGE AND STABILITY
.........................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 16
PART II: SCIENTIFIC INFORMATION
................................................................................
17
PHARMACEUTICAL INFORMATION
.........................................................................
17
CLINICAL T